Saltar al contenido

§De dónde sale cada cifra

Toda cifra de esta página lleva su fuente, y cada fuente se verificó en PubMed antes de citarla. Lo que no pudimos verificar se dice que falta: en esta página hay 29 huecos declarados a propósito.

Un aviso sobre el conjunto: la mayoría de estas cifras vienen de metaanálisis cuyos autores califican su propia certeza de baja o muy baja. Eso no las invalida, porque son lo mejor que hay, pero sí obliga a usarlas como orientación de magnitud, no como constantes.

  1. Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421-53. PMID 24677189. https://doi.org/10.1007/s40263-014-0157-3
  2. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939-51. PMID 31303314. https://doi.org/10.1016/S0140-6736(19)31135-3
  3. Balijepalli C, Druyts E, Zoratti MJ, et al. Change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: a network meta-analysis. Schizophr Res Treatment. 2018;2018:1543034. PMID 29805808. https://doi.org/10.1155/2018/1543034
  4. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291-314. PMID 15456328. https://doi.org/10.2165/00003495-200464200-00003
  5. Gomez L, Stubbs B, Shirazi A, Vancampfort D, Gaughran F, Lally J. Lower bone mineral density at the hip and lumbar spine in people with psychosis versus controls: a comprehensive review and skeletal site-specific meta-analysis. Curr Osteoporos Rep. 2016;14(6):249-59. PMID 27696144. https://doi.org/10.1007/s11914-016-0325-0
  6. Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte JA. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry. 2010;71(3):338-47. PMID 20331935. 83 varones de 7 a 17 anos, tratados una media de 2,9 anos. https://doi.org/10.4088/JCP.08m04595gre
  7. Papazoglou AS, Leite AR, Moysidis DV, et al. Serum prolactin levels and mortality in adults without prolactinoma: a meta-analysis. J Clin Endocrinol Metab. 2024;109(8):e1652-64. PMID 38366650. 28 estudios revisados, 14 agrupables, 23.596 personas. Poblacion general, no psiquiatrica. https://doi.org/10.1210/clinem/dgae087
  8. Gopal S, Lane R, Nuamah I, et al. Evaluation of potentially prolactin-related adverse events and sexual maturation in adolescents with schizophrenia treated with paliperidone extended-release for 2 years: a post hoc analysis of an open-label multicenter study. CNS Drugs. 2017;31(9):797-808. PMID 28660406. 400 adolescentes de 12 a 17 anos; 184 completaron los dos anos. Analisis post hoc, abierto y sin placebo, financiado por el fabricante. https://doi.org/10.1007/s40263-017-0437-9
  9. Giri D, Sanam T, Oppenheim A, Senniappan S, Das U. Management of risperidone induced hyperprolactinemia in an adolescent with severe autism. Horm Res Paediatr. 2015;84(Suppl 1):P3-1114. 54.º congreso de la ESPE, Barcelona. Un caso. Resumen de congreso: no esta indexado en PubMed y no tiene DOI, y por eso se cita solo para lo que un caso puede sostener. https://abstracts.eurospe.org/hrp/0084/hrp0084p3-1114
  10. Li X, Tang Y, Wang C. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PLoS One. 2013;8(8):e70179. PMID 23936389. https://doi.org/10.1371/journal.pone.0070179
  11. Zhang L, Qi H, Xie YY, et al. Efficacy and safety of adjunctive aripiprazole, metformin, and paeoniae-glycyrrhiza decoction for antipsychotic-induced hyperprolactinemia: a network meta-analysis of randomized controlled trials. Front Psychiatry. 2021;12:728204. PMID 34658963. https://doi.org/10.3389/fpsyt.2021.728204
  12. Labad J, Montalvo I, González-Rodríguez A, et al. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: a systematic review and meta-analysis. Schizophr Res. 2020;222:88-96. PMID 32507371. https://doi.org/10.1016/j.schres.2020.04.031
  13. Meng M, Li W, Zhang S, et al. Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials. Shanghai Arch Psychiatry. 2015;27(1):4-17. PMID 25852251. https://doi.org/10.11919/j.issn.1002-0829.215014
  14. Landén M, Högberg P, Thase ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. J Clin Psychiatry. 2005;66(1):100-6. PMID 15669895. https://doi.org/10.4088/jcp.v66n0114
  15. Rothmore J. Antidepressant-induced sexual dysfunction. Med J Aust. 2020;212(7):329-34. PMID 32172535. https://doi.org/10.5694/mja2.50522
  16. de Boer MK, Castelein S, Wiersma D, Schoevers RA, Knegtering H. The facts about sexual (dys)function in schizophrenia: an overview of clinically relevant findings. Schizophr Bull. 2015;41(3):674-86. PMID 25721311. https://doi.org/10.1093/schbul/sbv001
  17. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry. 2001;62(Suppl 3):10-21. PMID 11229449 (sin DOI en el registro de PubMed).
  18. Winter J, Curtis K, Hu B, Clayton AH. Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management. Expert Opin Drug Saf. 2022;21(7):913-30. PMID 35255754. https://doi.org/10.1080/14740338.2022.2049753
  19. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259-66. PMID 19440080. https://doi.org/10.1097/JCP.0b013e3181a5233f
  20. Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev. 2013;2013(5):CD003382. PMID 23728643. 23 ECA, 1.886 personas. https://doi.org/10.1002/14651858.CD003382.pub3
  21. Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA. 2003;289(1):56-64. PMID 12503977. ECA doble ciego, 90 hombres. https://doi.org/10.1001/jama.289.1.56
  22. Nurnberg HG, Hensley PL, Heiman JR, Croft HA, DeBattista C, Paine S. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA. 2008;300(4):395-404. PMID 18647982. ECA doble ciego, 98 mujeres. https://doi.org/10.1001/jama.300.4.395
  23. Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry. 2004;65(1):62-7. PMID 14744170. ECA doble ciego, n = 42. https://doi.org/10.4088/jcp.v65n0110
  24. Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction. J Sex Med. 2015;12(10):2036-48. PMID 26331383. ECA cabeza a cabeza, n = 447. https://doi.org/10.1111/jsm.12980
  25. Landén M, Eriksson E, Agren H, Fahlén T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1999;19(3):268-71. PMID 10350034. El desenlace sexual no era el primario del ensayo. https://doi.org/10.1097/00004714-199906000-00012
  26. Michelson D, Bancroft J, Targum S, Kim Y, Tepner R. Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention. Am J Psychiatry. 2000;157(2):239-43. PMID 10671393. Negativo para buspirona y amantadina, 57 mujeres. https://doi.org/10.1176/appi.ajp.157.2.239
  27. Kang BJ, Lee SJ, Kim MD, Cho MJ. A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. Hum Psychopharmacol. 2002;17(6):279-84. PMID 12404672. Negativo, n = 37. https://doi.org/10.1002/hup.409
  28. Wheatley D. Triple-blind, placebo-controlled trial of Ginkgo biloba in sexual dysfunction due to antidepressant drugs. Hum Psychopharmacol. 2004;19(8):545-8. PMID 15378664. Negativo, n = 24. https://doi.org/10.1002/hup.627
  29. Healy D, Bahrick A, Bak M, et al. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2022;33(1):65-76. PMID 34719438. Criterios de consenso de panel, no de cohorte. https://doi.org/10.3233/JRS-210023
  30. Ben-Sheetrit J, Hermon Y, Birkenfeld S, Gutman Y, Csoka AB, Toren P. Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants. Ann Gen Psychiatry. 2023;22(1):15. PMID 37085865. Cohorte retrospectiva de 19 años, 12.302 hombres. https://doi.org/10.1186/s12991-023-00447-0
  31. Studt A, Gannon M, Orzel J, Vaughan A, Pearlman AM. Characterizing post-SSRI sexual dysfunction and its impact on quality of life through an international online survey. Int J Risk Saf Med. 2021;32(4):321-9. PMID 34366299. Encuesta en línea autoseleccionada, n = 239. https://doi.org/10.3233/JRS-210039
  32. Orlova Y, Rizzoli P, Loder E. Association of coprescription of triptan antimigraine drugs and SSRI or SNRI antidepressants with serotonin syndrome. JAMA Neurol. 2018;75(5):566-72. PMID 29482205. 19.017 pacientes coprescritos, 30.928 personas-año. https://doi.org/10.1001/jamaneurol.2017.5144
  33. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust. 2007;187(6):361-5. PMID 17874986. https://doi.org/10.5694/j.1326-5377.2007.tb01282.x
  34. Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-42. PMID 12925718. 2.222 ingresos por sobredosis. https://doi.org/10.1093/qjmed/hcg109
  35. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-13. PMID 2035713. Revision de 12 informes y 38 casos, no una cohorte. https://doi.org/10.1176/ajp.148.6.705
  36. Chiew AL, Isbister GK. Serotonin toxicity: pathophysiology, incidence, clinical assessment and management. Br J Clin Pharmacol. 2024;91(3):654-61. PMID 38926083. https://doi.org/10.1111/bcp.16152
  37. Bai AD, McKenna S, Wise H, Loeb M, Gill SS. Association of linezolid with risk of serotonin syndrome in patients receiving antidepressants. JAMA Netw Open. 2022;5(12):e2247426. PMID 36534400. 1.134 ambulatorios, cohorte poblacional con emparejamiento por puntaje de propension. https://doi.org/10.1001/jamanetworkopen.2022.47426
  38. King E, Rotella JA. Efficacy of cyproheptadine in the management of serotonin toxicity following deliberate self-poisoning: a systematic review. Emerg Med Australas. 2025;37(1):e14554. PMID 39791184. Certeza muy baja: la eficacia no quedo establecida. https://doi.org/10.1111/1742-6723.14554
  39. Lao KSJ, Zhao J, Blais JE, et al. Antipsychotics and risk of neuroleptic malignant syndrome: a population-based cohort and case-crossover study. CNS Drugs. 2020;34(11):1165-75. PMID 33010024. https://doi.org/10.1007/s40263-020-00767-9
  40. Rogers JP, Oldham MA, Fricchione G, et al. Evidence-based consensus guidelines for the management of catatonia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2023;37(4):327-69. PMID 37039129. https://doi.org/10.1177/02698811231158232
  41. Gurrera RJ, Caroff SN, Cohen A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011;72(9):1222-8. PMID 21733489. https://doi.org/10.4088/JCP.10m06438
  42. Ware MR, Feller DB, Hall KL. Neuroleptic malignant syndrome: diagnosis and management. Prim Care Companion CNS Disord. 2018;20(1):17r02185. PMID 29325237. https://doi.org/10.4088/PCC.17r02185
  43. Guinart D, Misawa F, Rubio JM, et al. A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome. Acta Psychiatr Scand. 2021;144(4):329-41. PMID 34358327. https://doi.org/10.1111/acps.13359
  44. Kuhlwilm L, Schönfeldt-Lecuona C, Gahr M, Connemann BJ, Keller F, Sartorius A. The neuroleptic malignant syndrome: a systematic case series analysis focusing on therapy regimes and outcome. Acta Psychiatr Scand. 2020;142(3):233-41. PMID 32659853. https://doi.org/10.1111/acps.13215
  45. Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264-78. PMID 28146614. https://doi.org/10.4088/JCP.16r10832
  46. Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17(3):330-40. PMID 30192088. https://doi.org/10.1002/wps.20579
  47. Bergman H, Walker DM, Nikolakopoulou A, Soares-Weiser K, Adams CE. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technol Assess. 2017;21(43):1-218. PMID 28812541. https://doi.org/10.3310/hta21430
  48. Kalniunas A, Chakrabarti I, Mandalia R, Munjiza J, Pappa S. The relationship between antipsychotic-induced akathisia and suicidal behaviour: a systematic review. Neuropsychiatr Dis Treat. 2021;17:3489-97. PMID 34887662. https://doi.org/10.2147/NDT.S337785
  49. Gerolymos C, Barazer R, Yon DK, Loundou A, Boyer L, Fond G. Drug efficacy in the treatment of antipsychotic-induced akathisia: a systematic review and network meta-analysis. JAMA Netw Open. 2024;7(3):e241527. PMID 38451521. https://doi.org/10.1001/jamanetworkopen.2024.1527
  50. Lima AR, Bacalcthuk J, Barnes TRE, Soares-Weiser K. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2004;(4):CD001946. PMID 15495022. https://doi.org/10.1002/14651858.CD001946.pub2
  51. Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TR. Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2002;(1):CD001950. PMID 11869614. Un solo ensayo utilizable, n = 27. https://doi.org/10.1002/14651858.CD001950
  52. Mancini V, Latreche C, Fanshawe JB, et al. Anticholinergic burden and cognitive function in psychosis: a systematic review and meta-analysis. Am J Psychiatry. 2025;182(4):349-59. PMID 40007252. https://doi.org/10.1176/appi.ajp.20240260
  53. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476-84. PMID 28320223. https://doi.org/10.1176/appi.ajp.2017.16091037
  54. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604. PMID 28668671. https://doi.org/10.1016/S2215-0366(17)30236-5
  55. Cohen D. Clozapine and gastrointestinal hypomotility. CNS Drugs. 2017;31(12):1083-91. PMID 29230675. https://doi.org/10.1007/s40263-017-0481-5
  56. Every-Palmer S, Inns SJ, Grant E, Ellis PM. Effects of clozapine on the gut: cross-sectional study of delayed gastric emptying and small and large intestinal dysmotility. CNS Drugs. 2019;33(1):81-91. PMID 30456745. https://doi.org/10.1007/s40263-018-0587-4
  57. Cohen D, Bogers JPAM, van Dijk D, Bakker B, Schulte PFJ. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry. 2012;73(10):1307-12. PMID 23140648. https://doi.org/10.4088/JCP.11r06977
  58. Shirazi A, Stubbs B, Gomez L, et al. Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis. Int J Mol Sci. 2016;17(6):863. PMID 27271593. https://doi.org/10.3390/ijms17060863
  59. Every-Palmer S, Nowitz M, Stanley J, et al. Clozapine-treated patients have marked gastrointestinal hypomotility, the probable basis of life-threatening gastrointestinal complications: a cross sectional study. EBioMedicine. 2016;5:125-34. PMID 27077119. https://doi.org/10.1016/j.ebiom.2016.02.020
  60. Handley SA, Every-Palmer S, Ismail A, Flanagan RJ. Clozapine-induced gastrointestinal hypomotility: presenting features and outcomes, UK pharmacovigilance reports, 1992-2017. Br J Psychiatry. 2022;220(6):355-63. PMID 35164895. https://doi.org/10.1192/bjp.2022.24
  61. Every-Palmer S, Ellis PM. Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal slow gut reactions, and comparison with international drug safety advice. CNS Drugs. 2017;31(8):699-709. PMID 28623627. https://doi.org/10.1007/s40263-017-0448-6
  62. Flanagan RJ, Handley SA, James C, et al. Clozapine-induced gastrointestinal hypomotility: UK pharmacovigilance reports, 2018-2022. BJPsych Open. 2025;11(3):e79. PMID 40162866. https://doi.org/10.1192/bjo.2025.29
  63. Every-Palmer S, Ellis PM, Nowitz M, et al. The Porirua protocol in the treatment of clozapine-induced gastrointestinal hypomotility and constipation: a pre- and post-treatment study. CNS Drugs. 2017;31(1):75-85. PMID 27826741. https://doi.org/10.1007/s40263-016-0391-y
  64. Sundermann M, Every-Palmer S, Barclay M, Chin PKL. A clinical decision support alert to promote timely laxative use in in-patients prescribed clozapine. BJPsych Open. 2025;11(2):e51. PMID 40079118. https://doi.org/10.1192/bjo.2025.1
  65. Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(6):811-9. PMID 24777151. https://doi.org/10.1038/ajg.2014.82
  66. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64-77. PMID 31860457. https://doi.org/10.1016/S2215-0366(19)30416-X
  67. Fitzgerald I, Sahm LJ, Byrne A, et al. Predicting antipsychotic-induced weight gain in first episode psychosis: a field-wide systematic review and meta-analysis. Eur Psychiatry. 2023;66(1):e42. PMID 37278237. https://doi.org/10.1192/j.eurpsy.2023.2417
  68. Zhang JP, Lencz T, Zhang RX, et al. Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis. Schizophr Bull. 2016;42(6):1418-37. PMID 27217270. 46 muestras, 6.700 pacientes. https://doi.org/10.1093/schbul/sbw058
  69. Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ. 2018;361:k1951. PMID 29793997. https://doi.org/10.1136/bmj.k1951
  70. Stogios N, Agarwal SM, Maksyutynska K, et al. Pharmacological interventions for weight reduction in patients with schizophrenia treated with antipsychotics: a systematic review and network meta-analysis. JAMA Psychiatry. 2026. PMID 42418179. https://doi.org/10.1001/jamapsychiatry.2026.1814
  71. Hegde NC, Mishra A, Maiti R, et al. Pharmacological interventions for antipsychotic-induced weight gain in schizophrenia: a network meta-analysis. Gen Hosp Psychiatry. 2024;90:12-21. PMID 38878592. https://doi.org/10.1016/j.genhosppsych.2024.06.003
  72. Chen X, Wang DD, Li ZP. Time course and dose effect of metformin on weight in patients with different disease states. Expert Rev Clin Pharmacol. 2020;13(10):1169-77. PMID 32940086. Tiempo hasta la mitad del efecto maximo: 45,5 semanas. https://doi.org/10.1080/17512433.2020.1822164
  73. Calkin CV, Chengappa KNR, Cairns K, et al. Treating insulin resistance with metformin as a strategy to improve clinical outcomes in treatment-resistant bipolar depression (TRIO-BD): a randomized, quadruple-masked, placebo-controlled clinical trial. J Clin Psychiatry. 2022;83(2):21m14022. PMID 35120288. n = 45. La comparacion principal es conversores frente a no conversores, un subgrupo posterior a la aleatorizacion, no metformina frente a placebo. https://doi.org/10.4088/JCP.21m14022
  74. Kang M, Liu H, Hui J, et al. Metformin use on the risks of depression and anxiety in people with type 2 diabetes. Commun Med (Lond). 2025;5(1):302. PMID 40691522. UK Biobank, 11.379 pacientes con diabetes tipo 2. https://doi.org/10.1038/s43856-025-01006-2
  75. Dodd S, Sominsky L, Siskind D, et al. The role of metformin as a treatment for neuropsychiatric illness. Eur Neuropsychopharmacol. 2022;64:32-43. PMID 36191545. Revision narrativa. https://doi.org/10.1016/j.euroneuro.2022.09.002
  76. Battini V, Cirnigliaro G, Leuzzi R, et al. The potential effect of metformin on cognitive and other symptom dimensions in patients with schizophrenia and antipsychotic-induced weight gain: a systematic review, meta-analysis, and meta-regression. Front Psychiatry. 2023;14:1215807. PMID 37502816. https://doi.org/10.3389/fpsyt.2023.1215807
  77. Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk (CAMP). Am J Psychiatry. 2011;168(9):947-56. PMID 21768610. https://doi.org/10.1176/appi.ajp.2011.10111609
  78. Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14(3):339-47. PMID 26407790. https://doi.org/10.1002/wps.20252
  79. Stubbs B, Vancampfort D, De Hert M, Mitchell AJ. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand. 2015;132(2):144-57. PMID 25943829. https://doi.org/10.1111/acps.12439
  80. Fuller PM, Saper CB, Lu J. The pontine REM switch: past and present. J Physiol. 2007;584(Pt 3):735-41. PMID 17884926. https://doi.org/10.1113/jphysiol.2007.140160
  81. Postuma RB, Gagnon JF, Tuineaig M, et al. Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal? Sleep. 2013;36(11):1579-85. PMID 24179289. https://doi.org/10.5665/sleep.3102
  82. Schramm PJ, Poland RE, Rao U. Bupropion response on sleep quality in patients with depression. Eur Neuropsychopharmacol. 2013;24(2):207-14. PMID 24239431. https://doi.org/10.1016/j.euroneuro.2013.09.007
  83. DelRosso LM, Mogavero MP, Fickensher A, et al. Effects of bupropion and SSRI antidepressants on leg movement activity and chin muscle tone during sleep in adolescents. J Clin Sleep Med. 2023;19(1):151-61. PMID 36073843. https://doi.org/10.5664/jcsm.10282
  84. Wu Z, Wu J, Xie C, Wang L, Li H, Zhang M. Risk factors for rapid eye-movement sleep-related behavioral disorders (RBDs): a systematic review and meta-analysis. Gen Hosp Psychiatry. 2022;79:118-27. PMID 36375340. https://doi.org/10.1016/j.genhosppsych.2022.10.009
  85. Alexandres CA, McCarter SJ, Tabatabai GM, et al. Phenoconversion in women and men with isolated REM sleep behavior disorder: a retrospective cohort study. Neurology. 2024;103(10):e209993. PMID 39454123. 372 pacientes de la Clinica Mayo, mediana de seguimiento 6,0 años. https://doi.org/10.1212/WNL.0000000000209993
  86. McCarter SJ, St Louis EK, Boeve BF. REM sleep behavior disorder and REM sleep without atonia as an early manifestation of degenerative neurological disease. Curr Neurol Neurosci Rep. 2012;12(2):182-92. PMID 22328094. https://doi.org/10.1007/s11910-012-0253-z
  87. Feige B, Voderholzer U, Riemann D, Dittmann R, Hohagen F, Berger M. Fluoxetine and sleep EEG: effects of a single dose, subchronic treatment, and discontinuation in healthy subjects. Neuropsychopharmacology. 2002;26(2):246-58. PMID 11790520. https://doi.org/10.1016/S0893-133X(01)00314-1
  88. Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA, Huffman JC. QT prolongation, torsades de pointes, and psychotropic medications: a 5-year update. Psychosomatics. 2018;59(2):105-22. PMID 29275963. Revision narrativa NO sistematica, con busqueda estructurada en PubMed desde 2012; firmada por psiquiatras del Massachusetts General y cardiologos electrofisiologos de la Mayo. Es la fuente primaria de la nota del ACLP. https://doi.org/10.1016/j.psym.2017.10.009
  89. Funk MC, Beach SR, Bostwick JR, et al. QTc prolongation and psychotropic medications. Am J Psychiatry. 2020;177(3):273-4. PMID 32114782. Documento de recursos de la APA, con el aval del American College of Cardiology. No es una guia de practica clinica, y sus autores lo dicen. https://doi.org/10.1176/appi.ajp.2019.1760501
  90. Funk MC, Lou J. The fundamentals of QTc: understanding risks and preventing problems. Psychiatric Times. 2021;38(11). Revision narrativa de la misma primera autora del documento de la APA. https://www.psychiatrictimes.com/view/the-fundamentals-of-qtc
  91. Physicians «over-cautious about drug risks». ACLP News, marzo de 2018. Academy of Consultation-Liaison Psychiatry. Nota de prensa de sociedad cientifica sobre el trabajo de Beach y colaboradores, no un articulo revisado por pares. https://clpsychiatry.org/aclp-news/y2018/m03/qt-prolongation-drug-risk/
  92. Zivin K, Pfeiffer PN, Bohnert ASB, et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry. 2013;170(6):642-50. PMID 23640689. Cohorte retrospectiva de la Veterans Health Administration: 618.450 personas con citalopram y 365.898 con sertralina. https://doi.org/10.1176/appi.ajp.2013.12030408
  93. Rector TS, Adabag S, Cunningham F, Nelson D, Dieperink E. Outcomes of citalopram dosage risk mitigation in a veteran population. Am J Psychiatry. 2016;173(9):896-902. PMID 27166093. 35.848 veteranos que tomaban mas de 40 mg cuando se emitio la alerta. Retrospectivo: la reduccion de dosis no se asigno al azar. https://doi.org/10.1176/appi.ajp.2016.15111444
  94. Straley CM, Sochacki M, Reed E, Carr CN, Baugh TB. Comparison of the effect of citalopram, bupropion, sertraline, and tricyclic antidepressants on QTc: a cross-sectional study. J Affect Disord. 2021;296:476-84. PMID 34649181. Transversal, 487 sujetos y 798 electrocardiogramas; 95 % varones, edad media 61 anos. https://doi.org/10.1016/j.jad.2021.08.149
  95. Cheng SL, Hsu TW, Kao YC, et al. Haloperidol in treating delirium, reducing mortality, and preventing delirium occurrence: Bayesian and frequentist meta-analyses. Crit Care. 2025;29(1):126. PMID 40114217. Doce ECA doble ciego contra placebo: siete de TRATAMIENTO (n = 1.767) y cinco de PREVENCION (n = 2.509). Analiza los mismos datos con estadistica frecuentista y bayesiana, y las dos lecturas no dicen lo mismo. https://doi.org/10.1186/s13054-025-05342-6
  96. Salluh JIF, Wang H, Schneider EB, et al. Outcome of delirium in critically ill patients: systematic review and meta-analysis. BMJ. 2015;350:h2538. PMID 26041151. 42 estudios y 16.595 pacientes criticos. Es ASOCIACION, no efecto de un tratamiento. https://doi.org/10.1136/bmj.h2538
  97. Andersen-Ranberg NC, Poulsen LM, Perner A, et al. Haloperidol for the treatment of delirium in ICU patients (AID-ICU). N Engl J Med. 2022;387(26):2425-35. PMID 36286254. ECA multicentrico con placebo, 1.000 pacientes. El desenlace principal NO fue significativo; la diferencia de mortalidad a 90 dias es un desenlace secundario. https://doi.org/10.1056/NEJMoa2211868
  98. Girard TD, Exline MC, Carson SS, et al. Haloperidol and ziprasidone for treatment of delirium in critical illness (MIND-USA). N Engl J Med. 2018;379(26):2506-16. PMID 30346242. ECA doble ciego con placebo, 566 pacientes con delirium. https://doi.org/10.1056/NEJMoa1808217
  99. Devlin JW, Skrobik Y, Gelinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU (PADIS). Crit Care Med. 2018;46(9):e825-73. PMID 30113379. Guia de practica clinica de la Society of Critical Care Medicine: 37 recomendaciones, solo tres fuertes. https://doi.org/10.1097/CCM.0000000000003299
  100. Zhang WF, Tan YL, Zhang XY, Chan RCK, Wu HR, Zhou DF. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(5):615-21. PMID 20868638. Ensayo unico, sin replicar. https://doi.org/10.4088/JCP.09m05125yel
  101. Solmi M, Fornaro M, Caiolo S, et al. Efficacy and acceptability of pharmacological interventions for tardive dyskinesia: a systematic review and network meta-analysis. Mol Psychiatry. 2024;30(3):1207-22. PMID 39695322. https://doi.org/10.1038/s41380-024-02733-z
  102. Soares-Weiser K, Maayan N, Bergman H. Vitamin E for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;1(1):CD000209. PMID 29341067. https://doi.org/10.1002/14651858.CD000209.pub3
  103. Lerner V, Bergman J, Statsenko N, Miodownik C. Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2004;65(11):1550-4. PMID 15554771. https://doi.org/10.4088/jcp.v65n1118

Siguiente paso

Por qué ocurrenPrincipios básicos →Quién los produceTodos los fármacos →En qué cuadroDiagnósticos →